Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
Immunotherapy, especially immune checkpoint inhibitor (ICI) therapy, has yielded remarkable outcomes for some patients with solid cancers, but others do not respond to these treatments. Recent research has identified the gut microbiota as a key modulator of immune responses, suggesting that its comp...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512683/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556640033144832 |
|---|---|
| author | Mi Young Lim Seungpyo Hong Young-Do Nam |
| author_facet | Mi Young Lim Seungpyo Hong Young-Do Nam |
| author_sort | Mi Young Lim |
| collection | DOAJ |
| description | Immunotherapy, especially immune checkpoint inhibitor (ICI) therapy, has yielded remarkable outcomes for some patients with solid cancers, but others do not respond to these treatments. Recent research has identified the gut microbiota as a key modulator of immune responses, suggesting that its composition is closely linked to responses to ICI therapy in cancer treatment. As a result, the gut microbiome is gaining attention as a potential biomarker for predicting individual responses to ICI therapy and as a target for enhancing treatment efficacy. In this review, we discuss key findings from human observational studies assessing the effect of antibiotic use prior to ICI therapy on outcomes and identifying specific gut bacteria associated with favorable and unfavorable responses. Moreover, we review studies investigating the possibility of patient outcome prediction using machine learning models based on gut microbiome data before starting ICI therapy and clinical trials exploring whether gut microbiota modulation, for example via fecal microbiota transplantation or live biotherapeutic products, can improve results of ICI therapy in patients with cancer. We also briefly discuss the mechanisms through which the gut microbial-derived products influence immunotherapy effectiveness. Further research is necessary to fully understand the complex interactions between the host, gut microbiota, and immunotherapy and to develop personalized strategies that optimize responses to ICI therapy. |
| format | Article |
| id | doaj-art-5bc0e0b994f64ac4ab5c7f1f63ff7392 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-5bc0e0b994f64ac4ab5c7f1f63ff73922025-01-07T06:47:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15126831512683Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a reviewMi Young Lim0Seungpyo Hong1Young-Do Nam2Personalized Diet Research Group, Korea Food Research Institute, Wanju-gun, Jeollabuk-do, Republic of KoreaDepartment of Molecular Biology, Jeonbuk National University, Jeonju-si, Jeollabuk-do, Republic of KoreaPersonalized Diet Research Group, Korea Food Research Institute, Wanju-gun, Jeollabuk-do, Republic of KoreaImmunotherapy, especially immune checkpoint inhibitor (ICI) therapy, has yielded remarkable outcomes for some patients with solid cancers, but others do not respond to these treatments. Recent research has identified the gut microbiota as a key modulator of immune responses, suggesting that its composition is closely linked to responses to ICI therapy in cancer treatment. As a result, the gut microbiome is gaining attention as a potential biomarker for predicting individual responses to ICI therapy and as a target for enhancing treatment efficacy. In this review, we discuss key findings from human observational studies assessing the effect of antibiotic use prior to ICI therapy on outcomes and identifying specific gut bacteria associated with favorable and unfavorable responses. Moreover, we review studies investigating the possibility of patient outcome prediction using machine learning models based on gut microbiome data before starting ICI therapy and clinical trials exploring whether gut microbiota modulation, for example via fecal microbiota transplantation or live biotherapeutic products, can improve results of ICI therapy in patients with cancer. We also briefly discuss the mechanisms through which the gut microbial-derived products influence immunotherapy effectiveness. Further research is necessary to fully understand the complex interactions between the host, gut microbiota, and immunotherapy and to develop personalized strategies that optimize responses to ICI therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512683/fullgut microbiomeimmunotherapyimmune checkpoint inhibitorsolid cancerresponseprediction |
| spellingShingle | Mi Young Lim Seungpyo Hong Young-Do Nam Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review Frontiers in Immunology gut microbiome immunotherapy immune checkpoint inhibitor solid cancer response prediction |
| title | Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review |
| title_full | Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review |
| title_fullStr | Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review |
| title_full_unstemmed | Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review |
| title_short | Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review |
| title_sort | understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies a review |
| topic | gut microbiome immunotherapy immune checkpoint inhibitor solid cancer response prediction |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512683/full |
| work_keys_str_mv | AT miyounglim understandingtheroleofthegutmicrobiomeinsolidtumorresponsestoimmunecheckpointinhibitorsforpersonalizedtherapeuticstrategiesareview AT seungpyohong understandingtheroleofthegutmicrobiomeinsolidtumorresponsestoimmunecheckpointinhibitorsforpersonalizedtherapeuticstrategiesareview AT youngdonam understandingtheroleofthegutmicrobiomeinsolidtumorresponsestoimmunecheckpointinhibitorsforpersonalizedtherapeuticstrategiesareview |